Catapult Ventures
VC Fund
Leicester, United Kingdom
Catapult Ventures is a VC fund in Leicester focused on Health Care and Biotechnology. The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
- Total investments:
- 105
- Last investment:
- Lead investor:
- 25%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Catapult Ventures invests in
Stages Catapult Ventures invests in
Countries Catapult Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $150k–$5.6M
- Series A
- $1.6M–$26M
Investment Focus
Industry
- Health Care 25 (24%)
- Biotechnology 23 (22%)
- Medical 14 (13%)
- Pharmaceutical 14 (13%)
- Software 13 (12%)
Stage
- Funding Round 53 (50%)
- Seed 20 (19%)
- Series A 7 (7%)
- Series B 4 (4%)
- Pre-Seed 2 (2%)
Country
- United Kingdom 71 (68%)
- United States 10 (10%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Spencer
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Corinne Lawrence
Group Financial Controller
|
Group Financial Controller | Total investments: 0 | Find email | |
David Whitcombe
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
David Whitcombe
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Duncan Cameron
Chief Financial Officer & Director
|
Chief Financial Officer & Director | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Anello Photonics
|
Anello Photonics is a technology company developing a silicon photonic optical gyroscope to navigate, position, and motion track autonomous applications in challenging GPS-jammed and spoofed environments. The company's technology portfolio spans over 28 issued patents, and over 44 pending patents, and includes an AI-based sensor fusion engine.It serves the robotics, defense, construction, agriculture, and autonomous vehicles industries. | Series B / Nov 18, 2024 | |
Pickle Robot
|
Pickle Robot is a low cost, collaborative package handling robot that automates several key tasks along the e-commerce supply chain.Package handling is a physically demanding job with extremely high rates of turnover. The rising costs of shipping, comprised of 2/3rds labor, have become a major bottleneck to continued growth in e-commerce.Dill is the first robot from the Pickle Robot Company. It works multiple shifts, communicates with its human collaborators, and is rapidly developing new skills in handling e-commerce parcels: such as loading/unloading of feeder trucks, palletizing/depalletizing, and preloading of last mile delivery vans, trucks, and parcel cars. | $50M / Series B / Nov 11, 2024 | |
Path Robotics
|
Path Robotics designs robotic welding systems that incorporate AI and machine learning for enhanced precision and adaptability. These systems automate repetitive tasks, enabling manufacturers to increase productivity while minimizing upfront costs. The company addresses workforce challenges in the manufacturing sector through effective automationsolutions. | $100M / Series D / Oct 14, 2024 | |
CroBio
|
CroBio is a start-up founded by individuals specialising in microbiology and engineering. The company has a vision to create an environmentally sustainable solution to managing global agricultural drought.The companies current technology is based on a genetically engineered root-associated bacteria that has self-sustaining biologically activewater retention. The bacteria naturally occur around the roots of many crops such as corn, wheat and soybean. By exploiting these symbiotic relationships, we are able to engineer beneficial traits. | $1.6M / Seed / Apr 23, 2024 | |
Pencil Biosciences
|
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available. | $7.3M / Seed / Sep 28, 2023 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M / Seed / Jan 10, 2023 | |
|
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M / Seed / Jan 10, 2023 | |
Urban Machine
|
Salvaging the past to build the future- Stealth Startup | $5.6M / Seed / Dec 08, 2022 | |
|
Pickle Robot
|
Pickle Robot is a low cost, collaborative package handling robot that automates several key tasks along the e-commerce supply chain.Package handling is a physically demanding job with extremely high rates of turnover. The rising costs of shipping, comprised of 2/3rds labor, have become a major bottleneck to continued growth in e-commerce.Dill is the first robot from the Pickle Robot Company. It works multiple shifts, communicates with its human collaborators, and is rapidly developing new skills in handling e-commerce parcels: such as loading/unloading of feeder trucks, palletizing/depalletizing, and preloading of last mile delivery vans, trucks, and parcel cars. | $26M / Series A / Nov 15, 2022 | |
Strella Biotechnology
|
Strella biotech is a revenue-generating food supply chain company that provides data to optimize the produce supply chain via patented proprietary sensing technology. It specializes in the fields of supply chain management and big data.Strella was founded in 2018 by Jacob Jordan and Katherine Sizov and is based in Philadelphia, Pennsylvania,United States. | $8M / Series A / Jun 07, 2022 | |
| See all 105 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Catapult Ventures invest in?
Catapult Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Seed stage. Most of the 105 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Catapult Ventures's check size?
Catapult Ventures typically joins rounds of $150k–$5.6M at Seed and $1.6M–$26M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Catapult Ventures participates in.
How do I contact Catapult Ventures?
Public channels for Catapult Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Catapult Ventures?
The team at Catapult Ventures includes Chris Spencer (Venture Partner), Corinne Lawrence (Group Financial Controller) and David Whitcombe (Venture Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
